How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

With hardware prices spiraling, AI vendors ramping up token costs, and models becoming drastically slimmer and more economical, running AI models locally isn’t just going to be a good idea whose time ...